Glaxosmithkline and Joe Gibbs Racing Join Forces in The "Racing ror Life" Health Screening Program at Bristol On-Site Mobile Health Unit Offers Free Screenings at Racetracks HUNTERSVILLE, N.C., Tuesday, March 23, 2004 -- GlaxoSmithKline ...
Glaxosmithkline and Joe Gibbs Racing Join Forces in The "Racing ror
Life" Health Screening Program at Bristol
On-Site Mobile Health Unit Offers Free Screenings at Racetracks
HUNTERSVILLE, N.C., Tuesday, March 23, 2004 -- GlaxoSmithKline (GSK), one of the world's leading research-based pharmaceutical companies, has joined forces with Joe Gibbs Racing (JGR), one of NASCAR's premier racing teams, to offer free health screenings at GSK's "Racing for Life" Mobile Health Exhibit. Officials at GSK and JGR announced that this mobile exhibit will appear at 23 races in 2004. The "Racing for Life" exhibit will be formally introduced with a green flag opening ceremony planned for Friday, March 26 at 10:00am at Bristol Motor Speedway immediately following the unveiling of the Wellbutrin XL (bupropion HCl extended-release tablets) race car. 2000 NASCAR NEXTEL Cup Champion Bobby Labonte, crew chief Michael McSwain, and team owner J.D. Gibbs will make a special appearance at this ceremony and will personally take advantage of the free health screenings offered within the exhibit.
The Wellbutrin XL car will be driven at its inaugural race by Bobby Labonte at the Food City 500 Race at Bristol Motor Speedway on Sunday, March 28. Depression is a common and under-treated medical condition that affects an estimated 13-14 million US adults yearly with a lifetime estimate of 33-35 million adults, and the Wellbutrin XL race car represents a GSK medicine indicated for the treatment of major depressive disorder in patients 18 years and older.
The "Racing for Life" exhibit expands into a patient education and health-screening center, and provides screenings and information on such health topics as hypertension, type II diabetes, osteoporosis, asthma, men's health, smoking cessation, migraine, and depression. Physicians will be on hand at the exhibit to answer questions from individuals who visit the exhibit.
Joe Gibbs knows the importance of maintaining good health from personal experience. Since being diagnosed with diabetes, he has followed a treatment regime that includes diet and medicines prescribed by his doctor to keep his disease under control.
"No one can expect a race car to run, let alone win races, if we don't constantly keep it well-maintained," said Joe Gibbs, JGR owner and head coach of the Washington Redskins. "Why should we expect our bodies to keep working without the appropriate maintenance? You should know the health risks you face, talk to your doctor, make the necessary adjustments to your lifestyle, and take medicines as prescribed by your doctor to take care of yourself. GlaxoSmithKline is offering a tremendous opportunity to fans at many of our races with this Mobile Health Exhibit. I encourage everyone to stop by and learn how you can better manage your health."
Bobby Labonte, who won the 2000 NASCAR NEXTEL Cup championship driving for JGR, does not suffer from depression, but he knows the importance from personal experience of maintaining good health and a positive attitude. He has dealt with asthma since childhood and understands the value of taking charge of one's health, talking to your doctor about your health, and following your doctor's advice.
"I'm proud to have GlaxoSmithKline as a major sponsor and help build awareness around the pervasiveness of depression among adults," Labonte said. "We can't take our health for granted, and visiting the exhibit, getting screened, taking the depression questionnaire, and discussing the results with your doctor could make a tremendous difference to you or someone you love."
"We worked very successfully with Bobby Labonte and Joe Gibbs Racing last year to raise awareness of asthma and its treatment," said Stan Hull, GSK senior vice president of the United States Pharmaceuticals. "This year, we're broadening our efforts to build awareness around the availability of options to treat depression, and offer a way for race fans to obtain information and free screenings for a number of disease areas in which GSK has expertise. I commend Joe, Bobby and the rest of the team for recognizing the importance of good health care, for sharing their own stories, and for joining us in this effort to help race fans and others improve their health."
SAFETY INFORMATION FOR WELLBUTRIN XL
Wellbutrin XLa (bupropion hydrochloride extended-release tablets) is contraindicated in patients who have or had a seizure disorder, patients being treated with ZYBAN® (bupropion hydrochloride) Sustained-Release Tablets, or any other medications that contain bupropion, patients who have or had bulimia or anorexia nervosa, patients undergoing abrupt discontinuation of alcohol or sedatives (including benzodiazepines), and patients taking MAO inhibitors. At least 14 days should elapse between discontinuation of an MAO inhibitor and initiation of treatment with WELLBUTRIN XL.
When treating depression, physicians should be aware that bupropion is associated with a risk of seizure, which is dose related. While WELLBUTRIN XL has not been formally evaluated in a clinical trial, its incidence of seizure may be similar to that of the immediate-release and the sustained-release formulations of bupropion, since it has demonstrated bioequivalence to both. At doses of up to 300 mg/day of the sustained-release formulation (WELLBUTRIN SR), the incidence of seizure is approximately 0.1%. At doses of 300 mg/day to 450 mg/day of the immediate release formulation (WELLBUTRIN® [bupropion HCl], the incidence of seizure is approximately 0.4%. To reduce the risk of seizures, please see WARNINGS in the Prescribing Information for patient selection considerations, including concomitant medications and dosing recommendations.
When treating patients with severe hepatic cirrhosis, extreme caution should be exercised and a reduced dosage and/or frequency is required to avoid accumulation.
There have been reports of hypertension, in some cases severe, in patients receiving bupropion alone and in combination with nicotine replacement therapy.